AT48641B - Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances. - Google Patents

Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances.

Info

Publication number
AT48641B
AT48641B AT48641DA AT48641B AT 48641 B AT48641 B AT 48641B AT 48641D A AT48641D A AT 48641DA AT 48641 B AT48641 B AT 48641B
Authority
AT
Austria
Prior art keywords
drug
ineffective
ergot
freed
production
Prior art date
Application number
Other languages
German (de)
Original Assignee
Knoll & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1907226468D external-priority patent/DE226468C/de
Application filed by Knoll & Co filed Critical Knoll & Co
Application granted granted Critical
Publication of AT48641B publication Critical patent/AT48641B/en

Links

Description

  

   <Desc/Clms Page number 1> 
 



  Verfahren zur Herstellung eines haltbaren, die therapeutisch wichtigen Bestandteile der Droge in ihren ursprünglichen Mengenverhältnissen enthaltenden, von unwirksamen und schädlichen Stoffen befreiten Präparates aus Mutterkorn. 



   Die grosse arzneiliche Bedeutung, die dem Mutterkorn zukommt, hat zu zahlreichen chemischen Untersuchungen geführt, deren Ergebnisse einander zum Teil widersprechen und noch keine   vollständige   Klarheit in dieses verwickelte Gebiet   gebracht haben.   Neuerdings haben'zwar Barger und Carr ("Journ. Chem. Soc."XCI, 1907, S. 337) und Barger und   Dale ("Chem.

   Ztbl."1907, I.,   S. 279) einige   dieser Widersprtiche aufgeklärt   und eine erhebliche Vereinfachung in der Benonnungsweiso und in der   pharmako ! ogischon Be-   
 EMI1.1 
 der Pharmakopöen zu gross zu sein scheint, als dass sie auf der   geringen Menge   Ergotoxin, die in ihnen enthalten ist (von   Barger und Carr   rein dargestellt),   beruhen könne   ; es sei vielmehr   wahrscheinlich,   dass irgend ein anderes wirksames Prinzip darin vorhanden ist". Über die Natur dieses wirksamen Prinzipes ist man noch vollständig im Unklaren. 



   Es ist bekannt, dass das Mutterkorn und seine Extrakte sich bald zersetzen, so   dass   
 EMI1.2 
 werden dürfen. Aber auch schon innerhalb dieses Zeitraumes nimmt ihre   Wirkungsweise     beträchtlich   ah und wird ihr therapeutische Wirkung sicher. 



   Es wurde nun gefunden, dass ein gut haltbares Produkt von der vollen Wirkung   der frischen Droge erhalten werden kann,   wenn der wässrige Auszug des entfetteten Mutterkorens nach dem Neutralisieren und Einengen mit hochprozentigem   A) kohol und     Äther erschöpfend behando) t wird.   Bei dieser Behandlung scheiden sich unwirksame Ballaststoffe (mit sehr geringen Mengen wirksamer Stoffe) aus, während der Hauptteil der wirksamen Stoffe in die   alkoholisch-ätherische Losung übergeht. Aus   dieser Lösung kann nun durch Einengen und Trocknen, vorteilhaft in der Luftleere, und nach Zumischen von Milchzucker oder anderen geeigneten Stoffen ein handliches Präparat gewonnen werden. das auf eine bestimmte   Wirkungsweise   eingestellt werden kann. 



   Beispiel : 10 kg gepulvertes und entfettetes Mutterkorn werden einige Male mit je 20   l   Wasser warm ausgezogen, die Auszüge mit Alkali neutralisiert und in der Luft- 
 EMI1.3 
 dem Filtrat werden bei Luftleere die Lösungsmittel entfernt ; der   Rückstand wird   nach   Zugabe von Milchzucker xur Trockne und   in Pulverform gebracht. 
 EMI1.4 




   <Desc / Clms Page number 1>
 



  Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances.



   The great medicinal importance of ergot has led to numerous chemical investigations, the results of which contradict one another and have not yet brought complete clarity to this complex area. Recently, Barger and Carr ("Journ. Chem. Soc." XCI, 1907, p. 337) and Barger and Dale ("Chem.

   Ztbl. "1907, I., p. 279) some of these contradictions cleared up and a considerable simplification in the designation and in the pharmako! Ogischon
 EMI1.1
 the pharmacopoeia seems to be too large to be based on the small amount of ergotoxine they contain (presented in pure form by Barger and Carr); it is rather probable that there is some other effective principle in it. "The nature of this effective principle is still completely in the dark.



   It is known that ergot and its extracts soon decompose, so that
 EMI1.2
 may be. But even within this period of time, their mode of action increases considerably and their therapeutic effect is certain.



   It has now been found that a well-preserved product can be obtained from the full effect of the fresh drug if the aqueous extract of the defatted motherwort is treated exhaustively after neutralization and concentration with high-percentage alcohol and ether. During this treatment, ineffective dietary fiber (with very small amounts of active substances) is eliminated, while the main part of the active substances passes into the alcoholic-ethereal solution. A handy preparation can now be obtained from this solution by concentration and drying, advantageously in a vacuum, and after adding lactose or other suitable substances. that can be adjusted to a specific mode of action.



   Example: 10 kg of powdered and defatted ergot is drawn out a few times with 20 l of warm water, the extracts are neutralized with alkali and then left in the air.
 EMI1.3
 The solvents are removed from the filtrate in a vacuum; after adding lactose, the residue is brought to dryness and into powder form.
 EMI1.4


 

Claims (1)

PATENT-ANSPUUOH : Vorfahren zur Herstellung eines haltbaren, die therapeutisch wichtigen Bestandteile der Droge in ihren ursprünglichen Mengenverhältnissen enthaltenden, von unwirksamen und schädlichen Stoffen befreiten Präparates aus'Mutterkorn, dadurch gekennzeichnet, dass der wässrige Auszug der Droge nach dem Neutralisieren und Einengen solange mit Alkohol und Äther versetzt wird, als noch ein Niederschlag entsteht. PATENT ANSPUUOH: Ancestors for the production of a durable preparation from 'mother corn' containing the therapeutically important components of the drug in their original proportions, freed from ineffective and harmful substances, characterized in that alcohol and ether are added to the aqueous extract of the drug after neutralization and concentration when a precipitate still forms.
AT48641D 1907-12-23 1908-11-09 Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances. AT48641B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1907226468D DE226468C (en) 1907-12-23

Publications (1)

Publication Number Publication Date
AT48641B true AT48641B (en) 1911-06-26

Family

ID=5866033

Family Applications (1)

Application Number Title Priority Date Filing Date
AT48641D AT48641B (en) 1907-12-23 1908-11-09 Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances.

Country Status (1)

Country Link
AT (1) AT48641B (en)

Similar Documents

Publication Publication Date Title
DE2655844C3 (en) Process for the production of anti-tumor substances
AT391315B (en) METHOD FOR PRODUCING ISOSILYBINE-FREE SILIBININE
CH650404A5 (en) ZEDRACHBORK EXTRACT WITH ANTINEOPLASTIC EFFECTIVENESS AND METHOD FOR THE PRODUCTION THEREOF.
DE1767098B1 (en) Process for obtaining a vasoactive drug from the leaves of Ginkgo biloba
AT48641B (en) Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances.
DE2010788A1 (en) Antigenic substances insoluble in water and process for their preparation
EP0668768B1 (en) Composition for controlling dermatomycoses and their agents, as well as transpiration and bodily odours
DE3734796A1 (en) METHOD FOR PRODUCING SOLUBLE AND / OR DIVISIBLE TABLETS AND TABLETS OBTAINED BY THIS METHOD
DE3101001A1 (en) METHOD FOR CONCENTRATING AND CLEANING THE ANTIHAEMOPHILIA FACTOR OR FACTOR VIII
DE226468C (en)
DE3000521A1 (en) SUBSTANCE WITH INTERFERON INDUCING ACTIVITY AND METHOD FOR THEIR PRODUCTION
DE1076888B (en) Process for the production of active substances that promote breathing for therapeutic purposes
DE950674C (en) Process for obtaining active substances from aqueous extracts of Echinacea species
DE657129C (en) Process for the production of solutions or extracts from bacteria, pollen or other plant cells
DE820788C (en) Process for the production of a yeast liver preparation
DE1910715A1 (en) Antimicrobial factors and their uses
DE435530C (en) Process for obtaining a therapeutically active substance
DE101255C (en)
DE711720C (en) Process for the enrichment and recovery of a substance which increases the formation of leukocytes
DE890562C (en) Process for the production of a medicament for the treatment of abnormal cell growth
AT287917B (en) Process for the preparation of an extract containing an allergen
DE432053C (en) Process for the production of Allium preparations
AT200257B (en)
AT300199B (en) Process for the production of a water-soluble powder from mineral spring waters
AT127117B (en) Process for the production of garlic preparations that are as odorless as possible.